Relative Bioavailability Study of Three Different Tablet Formulations of GSK1349572 50 mg and the Dose Proportionality of and Effect of Food on the Selected Formulation in Healthy Male and Female Volunteers (ING113674).
Phase of Trial: Phase I
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; Shionogi ViiV Healthcare LLC
- 19 Dec 2011 Results published in Antimicrobial Agents and Chemotherapy.
- 16 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 May 2010 Additional lead trial investigator (Medlock M) added as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History